Oct 10, 2019: A GW4 PhD position is available in the lab. We WELCOME applicants from ALL disciplines including Computer Science, Mathematics, Engineering, Physics, Bioinformatics, Pharmacy, Biology or Medicine. Details please see: https://bit.ly/2ppsM3C
Sep 25, 2019: Roanne has won the “Best Oral Presentation” Award at the European meeting on Comelment in human disease in Madrid. Congratulations!
July 01, 2019: Dr Zhou is now an Associate Theme Leader of Immunology, Infection and Inflammation in our College.
June 23, 2019: Welcome to Kayla Chan from School of Computer Science. She will do her master thesis in developing a webtool for lipidomic analysis.
June 20, 2019: In collaboration with researchers in mathematics and computer science, we worked on tackling healthcare challenges from industry using AI as highlighted in the University News.
June 18, 2019: Wellcome Adrian Chau joining the lab. He has recently been awarded a Wellcome Inspire Vacation Studentship and will work on Alzheimer’s disease and liver metabolism.
May 1, 2019: Dr. Zhou is invited to give a lecture at the Endocrinology, Nutrition & Metabolism & Cardiovascular seminar at the Southampton General Hospital (University of Southampton) on 25th June 2019.
The reason why the universe is eternal is that it does not live for itself; it gives life to others as it transforms.
- Lao Tzu (604 BC - 531 BC)
The scientific history of our world starts by observing the regularities in nature. Without Tycho’s meticulous data records of 1,006 stars, Kepler would not be able come to up with his 3 laws of planetary motion in the universe. In health research, we still await available and agreed notions of what underlying regularities exist. Recent advances in high throughput technologies and the rapid deluge of biomedical information enable us to creatively think about how to understand data, find the regularities and ultimately leverage them for improving our health. Responding to this challenge, the long-term research goal of our Lab is to develop and apply innovative systems biology approaches for disease diagnostics and therapeutics. We are specifically interested in harnessing and integrating different types of omics and clinical data to holistically understand the disease onset and progression. We are particularly interested in developing computational methods/tools and using them together with biology to better understand inflammation in the context of fatty liver disease and liver fibrosis.
Recently, using a systems-based approach, we have successfully
1) developed a new non-invasive tool for diagnosis of steatohepatitis (Zhou, J Hepatol., 2015), and found a new non-coding RNA for prognosis of breast cancer (Liu, Cell. Death Dis., 2019).
2) identified a novel therapeutic target for treating liver fibrosis (Qin, Scientific Reports).
3) found new functions of lipids and genes in progression of fatty liver disease (Luukkonen, J Hepatol., 2016; Luukkonen, J Hepatol., 2017).
#: co-first author;
*: Corresponding author
#, Y. Zhou
#, G. Liang, Y. Ling, W. Tan, L. Tan, R. Andrews, W. Zhong, X. Zhang, E. Song, C. Gong, Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p, Cell. Death Dis. 10 (2019) 55-018-1287-1. [PDF]
H. Kentala, A. Koponen, A.M. Kivela, R. Andrews, C. Li, Y. Zhou, V.M. Olkkonen, Analysis of ORP2-knockout hepatocytes uncovers a novel function in actin cytoskeletal regulation, FASEB J. 32 (2018) 1281-1295. [PDF]
P.K. Luukkonen, S. Sadevirta, Y. Zhou, B. Kayser, A. Ali, L. Ahonen, S. Lallukka, V. Pelloux, M. Gaggini, C. Jian, A. Hakkarainen, N. Lundbom, H. Gylling, A. Salonen, M. Oresic, T. Hyotylainen, M. Orho-Melander, A. Rissanen, A. Gastaldelli, K. Clement, L. Hodson, H. Yki-Jarvinen, Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars, Diabetes Care. 41 (2018) 1732-1739. (IF = 15.270) [PDF]
• Commented in the New York Times: raising the cautious over company-sponsored studies.
P.K. Luukkonen, Y. Zhou, P.A. Nidhina Haridas, O.P. Dwivedi, T. Hyotylainen, A. Ali, A. Juuti, M. Leivonen, T. Tukiainen, L. Ahonen, E. Scott, J.M. Palmer, J. Arola, M. Orho-Melander, P. Vikman, Q.M. Anstee, V.M. Olkkonen, M. Oresic, L. Groop, H. Yki-Jarvinen, Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD, J. Hepatol. 67 (2017) 128-136. (IF=18.946) [PDF]
S.Y. Qin, D.H. Lu, X.Y. Guo, W. Luo, B.L. Hu, X.L. Huang, M. Chen, J.X. Wang, S.J. Ma, X.W. Yang, H.X. Jiang
*, Y. Zhou
*, A deleterious role for Th9/IL-9 in hepatic fibrogenesis, Sci. Rep. 6 (2016) 18694. [PDF]
• Recommended Faculty of 1000 with ★★ as “New Finding”, “Novel Drug Target” and “Elegant study”: https://f1000.com/prime/726054174
Y. Zhou, M. Oresic, M. Leivonen, P. Gopalacharyulu, J. Hyysalo, J. Arola, A. Verrijken, S. Francque, L. Van Gaal, T. Hyotylainen, H. Yki-Jarvinen, Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites, Clin. Gastroenterol. Hepatol. 14 (2016) 1463-1472.e6. (IF=7.958) [PDF] • Highlighted in English media: Daily Express, Cardiff Star, New Atlas, Bioanalysis-zone, Cardiff University News etc. • Highlighted in Spanish media:Associació Catalana de Malalts d’Hepatitis.
#, Y. Zhou
#, S S. Sadevirta, M. Leivonen, J. Arola, M. Oresic, T. Hyotylainen, H. Yki-Jarvinen, Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease, J. Hepatol. 64 (2016) 1167-1175 (IF= 18.946). [PDF]
• Highly cited paper awarded by the Essential Science Indicators: citations ranked top 1% of the academic field of Clinical Medicine.
• Recommended by Faculty of 1000: https://f1000.com/prime/726082214
#, G. Llaurado
#, M. Oresic, T. Hyotylainen, M. Orho-Melander, H. Yki-Jarvinen, Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2, J. Hepatol. 62 (2015) 657-663 (IF= 18.946). [PDF]
P.K. Luukkonen, Y. Zhou, T. Hyotylainen, M. Leivonen, J. Arola, M. Orho-Melander, M. Oresic, H. Yki-Jarvinen, The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans, J. Hepatol. 65 (2016) 1263-1265. (IF= 18.946) [PDF]
S.Y. Qin, J. Liu, H.X. Jiang, B.L. Hu, Y. Zhou
*, V.M. Olkkonen
*. Association between baseline Lipoprotein (a) levels and restenosis after coronary stenting: Meta-analysis of 9fath cohort studies, Atherosclerosis. 227 (2013) 360-366. [PDF]
We are growing! Reach out if you are interested in joining us.
Complement Biology, Membrane Attack Complex, Bioinformatics
Drug Screening, Bioinformatics, Physiology
Genomic signatures, Gastroenterology
Systems Biology, Medicine
Developed by YZ lab
NASH App: An open-source data portal to overview the molecular landscape of Non-Alcoholic Steatohepatitis
Lipidomics Analysis Toolbox (Under going)